<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current Computer-Aided Drug Design</journal-id><journal-title-group><journal-title xml:lang="en">Current Computer-Aided Drug Design</journal-title><trans-title-group xml:lang="ru"><trans-title>Current Computer-Aided Drug Design</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1573-4099</issn><issn publication-format="electronic">1875-6697</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">643966</article-id><article-id pub-id-type="doi">10.2174/1573409919666230419094700</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Chemistry</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Computational Insight into the Mechanism of Action of DNA Gyrase Inhibitors; Revealing a New Mechanism</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Muhammed</surname><given-names>Muhammed</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Aki-Yalcin</surname><given-names>Esin</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Süleyman Demirel University</institution></aff><aff id="aff2"><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cyprus Health and Social Sciences University</institution></aff><pub-date date-type="pub" iso-8601-date="2024-03-01" publication-format="electronic"><day>01</day><month>03</month><year>2024</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="ru"/><fpage>224</fpage><lpage>235</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjeid.com/1573-4099/article/view/643966">https://rjeid.com/1573-4099/article/view/643966</self-uri><abstract xml:lang="en"><p id="idm46041443742592">Background:Discovery of novel antimicrobial agents is in need to deal with antibiotic resistance. Elucidating the mechanism of action for established drugs contributes to this endeavor. DNA gyrase is a therapeutic target used in the design and development of new antibacterial agents. Selective antibacterial gyrase inhibitors are available; however, resistance development against them is a big challenge. Hence, novel gyrase inhibitors with novel mechanisms are required.</p><p id="idm46041443746592">Objective:The aim of this study is to elucidate mode of action for existing DNA gyrase inhibitors and to pave the way towards discovery of novel inhibitors.</p><p id="idm46041443750560">Methods:In this study, the mechanism of action for selected DNA gyrase inhibitors available was carried out through molecular docking and molecular dynamics (MD) simulation. In addition, pharmacophore analysis, density functional theory (DFT) calculations, and computational pharmacokinetics analysis of the gyrase inhibitors were performed.</p><p id="idm46041443755616">Results:This study demonstrated that all the DNA gyrase inhibitors investigated, except compound 14, exhibit their activity by inhibiting gyrase B at a binding pocket. The interaction of the inhibitors at Lys103 was found to be essential for the binding. The molecular docking and MD simulation results revealed that compound 14 could act by inhibiting gyrase A. A pharmacophore model that consisted of the features that would help the inhibition effect was generated. The DFT analysis demonstrated 14 had relatively high chemical stability. Computational pharmacokinetics analysis revealed that most of the explored inhibitors were estimated to have good drug-like properties. Furthermore, most of the inhibitors were found to be non-mutagenic.</p><p id="idm46041443764992">Conclusion:In this study, mode of action elucidation through molecular docking and MD simulation, pharmacophore model generation, pharmacokinetic property prediction, and DFT study for selected DNA gyrase inhibitors were carried out. The outcomes of this study are anticipated to contribute to the design of novel gyrase inhibitors.</p></abstract><kwd-group xml:lang="en"><kwd>Antibacterial</kwd><kwd>DFT</kwd><kwd>DNA gyrase</kwd><kwd>molecular docking</kwd><kwd>MD simulation</kwd><kwd>pharmacophore.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Arandjelovic, P.; Doerflinger, M.; Pellegrini, M. Current and emerging therapies to combat persistent intracellular pathogens. Curr. Opin. Pharmacol., 2019, 48, 33-39. doi: 10.1016/j.coph.2019.03.013 PMID: 31051429</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Xu, Z.; Xu, D.; Zhou, W.; Zhang, X. Therapeutic potential of naturally occurring benzofuran derivatives and hybrids of benzofurans with other pharmacophores as antibacterial agents. Curr. Top. Med. Chem., 2022, 22(1), 64-82. doi: 10.2174/1568026621666211122162439 PMID: 34809548</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Yilmaz, S.; Yalcin, I.; Okten, S.; Onurdag, F.K.; Aki-Yalcin, E. Synthesis and investigation of binding interactions of 1,4-benzoxazine derivatives on topoisomerase IV in Acinetobacter baumannii. SAR QSAR Environ. Res., 2017, 28(11), 941-956. doi: 10.1080/1062936X.2017.1404490 PMID: 29206501</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ebenezer, O.; Singh-Pillay, A.; Koorbanally, N.A.; Singh, P. Antibacterial evaluation and molecular docking studies of pyrazolethiosemicarbazones and their pyrazolethiazolidinone conjugates. Mol. Divers., 2021, 25(1), 191-204. doi: 10.1007/s11030-020-10046-w PMID: 32086698</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pacios, O.; Blasco, L.; Bleriot, I.; Fernandez-Garcia, L.; González Bardanca, M.; Ambroa, A.; López, M.; Bou, G.; Tomás, M. Strategies to combat multidrug-resistant and persistent infectious diseases. Antibiotics, 2020, 9(2), 65. doi: 10.3390/antibiotics9020065 PMID: 32041137</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Qin, Y.; Xu, L.; Teng, Y.; Wang, Y.; Ma, P. Discovery of novel antibacterial agents: Recent developments in D‐alanyl‐D‐alanine ligase inhibitors. Chem. Biol. Drug Des., 2021, 98(3), 305-322. doi: 10.1111/cbdd.13899 PMID: 34047462</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wise, R.; Blaser, M.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G.; Davies, R.; Projan, S.; Dawson, M.; Monnet, D.; Keogh-Brown, M.; Hand, K.; Garner, S.; Findlay, D.; Morel, C.; Wise, R.; Bax, R.; Burke, F.; Chopra, I.; Czaplewski, L.; Finch, R.; Livermore, D.; Piddock, L.J.V.; White, T. The urgent need for new antibacterial agents. J. Antimicrob. Chemother., 2011, 66(9), 1939-1940. doi: 10.1093/jac/dkr261 PMID: 21700627</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mantravadi, P.; Kalesh, K.; Dobson, R.; Hudson, A.; Parthasarathy, A. The quest for novel antimicrobial compounds: Emerging trends in research, development, and technologies. Antibiotics, 2019, 8(1), 8. doi: 10.3390/antibiotics8010008 PMID: 30682820</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Collin, F.; Karkare, S.; Maxwell, A. Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl. Microbiol. Biotechnol., 2011, 92(3), 479-497. doi: 10.1007/s00253-011-3557-z PMID: 21904817</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schoeffler, A.J.; May, A.P.; Berger, J.M. A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function. Nucleic Acids Res., 2010, 38(21), 7830-7844. doi: 10.1093/nar/gkq665 PMID: 20675723</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Wang, J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol., 2002, 3(6), 430-440. doi: 10.1038/nrm831 PMID: 12042765</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Corbett, K.D.; Shultzaberger, R.K.; Berger, J.M. The C-terminal domain of DNA gyrase A adopts a DNA-bending β-pinwheel fold. Proc. Natl. Acad. Sci., 2004, 101(19), 7293-7298. doi: 10.1073/pnas.0401595101 PMID: 15123801</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Khan, T.; Sankhe, K.; Suvarna, V.; Sherje, A.; Patel, K.; Dravyakar, B. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents. Biomed. Pharmacother., 2018, 103, 923-938. doi: 10.1016/j.biopha.2018.04.021 PMID: 29710509</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hearnshaw, S.J.; Edwards, M.J.; Stevenson, C.E.; Lawson, D.M.; Maxwell, A. A new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. J. Mol. Biol., 2014, 426(10), 2023-2033. doi: 10.1016/j.jmb.2014.02.017 PMID: 24594357</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Petrella, S.; Capton, E.; Raynal, B.; Giffard, C.; Thureau, A.; Bonneté, F.; Alzari, P.M.; Aubry, A.; Mayer, C. Overall structures of Mycobacterium tuberculosis DNA gyrase reveal the role of a corynebacteriales GyrB-specific insert in ATPase activity. Structure, 2019, 27(4), 579-589.e5. doi: 10.1016/j.str.2019.01.004 PMID: 30744994</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod., 2016, 79(3), 629-661. doi: 10.1021/acs.jnatprod.5b01055 PMID: 26852623</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bush, N.G.; Diez-Santos, I.; Abbott, L.R.; Maxwell, A. Quinolones: Mechanism, lethality and their contributions to antibiotic resistance. Molecules, 2020, 25(23), 5662-5689. doi: 10.3390/molecules25235662 PMID: 33271787</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Blower, T.R.; Williamson, B.H.; Kerns, R.J.; Berger, J.M. Crystal structure and stability of gyrasefluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci., 2016, 113(7), 1706-1713. doi: 10.1073/pnas.1525047113 PMID: 26792525</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bradford, P.A.; Miller, A.A.; ODonnell, J.; Mueller, J.P. Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect. Dis., 2020, 6(6), 1332-1345. doi: 10.1021/acsinfecdis.0c00021 PMID: 32329999</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Muhammed, M.T.; Aki-Yalcin, E. Pharmacophore modeling in drug discovery: Methodology and current status. J Turkish Chem Soc Sect. Chem, 2021, 8, 759-772.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Muhammed, M.T.; Aki-Yalcin, E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem. Biol. Drug Des., 2019, 93(1), 12-20. doi: 10.1111/cbdd.13388 PMID: 30187647</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Muhammed, M.T. Son, Ç.D.; İzgü, F. Three dimensional structure prediction of panomycocin, a novel Exo-β-1,3-glucanase isolated from Wickerhamomyces anomalus NCYC 434 and the computational site-directed mutagenesis studies to enhance its thermal stability for therapeutic applications. Comput. Biol. Chem., 2019, 80, 270-277. doi: 10.1016/j.compbiolchem.2019.04.006 PMID: 31054539</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Fan, J.; Fu, A.; Zhang, L. Progress in molecular docking. Quant. Biol., 2019, 7(2), 83-89. doi: 10.1007/s40484-019-0172-y</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Muhammed, M.T.; Aki-Yalcin, E. Molecular docking: Principles, advances, and its applications in drug discovery. Lett. Drug Des. Discov., 2022, 19, 22. doi: 10.2174/1570180819666220922103109</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Kashid, B.B.; Ghanwat, A.A.; Khedkar, V.M.; Dongare, B.B.; Shaikh, M.H.; Deshpande, P.P.; Wakchaure, Y.B. Design, synthesis, in vitro antimicrobial, antioxidant evaluation, and molecular docking study of novel benzimidazole and benzoxazole derivatives. J. Heterocycl. Chem., 2019, 56(3), 895-908. doi: 10.1002/jhet.3467</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Alqahtani, S. In silico ADME-Tox modeling: Progress and prospects. Expert Opin. Drug Metab. Toxicol., 2017, 13(11), 1147-1158. doi: 10.1080/17425255.2017.1389897 PMID: 28988506</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Tretter, E.M.; Schoeffler, A.J.; Weisfield, S.R.; Berger, J.M. Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. Proteins, 2010, 78(2), 492-495. doi: 10.1002/prot.22600 PMID: 19787774</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Brvar, M.; Perdih, A.; Renko, M.; Anderluh, G.; Turk, D.; Solmajer, T. Structure-based discovery of substituted 4,5′-bithiazoles as novel DNA gyrase inhibitors. J. Med. Chem., 2012, 55(14), 6413-6426. doi: 10.1021/jm300395d PMID: 22731783</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Kim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B.A.; Thiessen, P.A.; Yu, B.; Zaslavsky, L.; Zhang, J.; Bolton, E.E. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res., 2021, 49(D1), D1388-D1395. doi: 10.1093/nar/gkaa971 PMID: 33151290</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Önem, E. Sarısu, H.C.; Özaydın, A.G.; Muhammed, M.T.; Ak, A. Phytochemical profile, antimicrobial, and anti‐quorum sensing properties of fruit stalks of Prunus avium L. Lett. Appl. Microbiol., 2021, 73(4), 426-437. doi: 10.1111/lam.13528 PMID: 34173244</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 2010, 31(2), 455-461. PMID: 19499576</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>BIOVIA, Dassault Systèmes, Discovery Studio. Comprehensive modeling and simulating for life sciences.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 2015, 1-2, 19-25. doi: 10.1016/j.softx.2015.06.001</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Schüttelkopf, A.W.; van Aalten, D.M.F. PRODRG: A tool for high-throughput crystallography of proteinligand complexes. Acta Crystallogr. D Biol. Crystallogr., 2004, 60(8), 1355-1363. doi: 10.1107/S0907444904011679 PMID: 15272157</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Bjelkmar, P.; Larsson, P.; Cuendet, M.A.; Hess, B.; Lindahl, E. Implementation of the charmm force field in GROMACS: Analysis of protein stability effects from correction maps, virtual interaction sites, and water models. J. Chem. Theory Comput., 2010, 6(2), 459-466. doi: 10.1021/ct900549r PMID: 26617301</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Akkoc, S.; Karatas, H.; Muhammed, M.T.; Kökbudak, Z.; Ceylan, A.; Almalki, F.; Laaroussi, H.; Ben Hadda, T. Drug design of new therapeutic agents: Molecular docking, molecular dynamics simulation, DFT and POM analyses of new Schiff base ligands and impact of substituents on bioactivity of their potential antifungal pharmacophore site. J. Biomol. Struct. Dyn., 2022, 1-14. doi: 10.1080/07391102.2022.2111360 PMID: 35968554</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Accelrys Discovery Studio Client 3.5, Accelrys Software Inc., San Diego, CA.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Gaussian 09, Revision B.01. Gaussian Inc., Wallingford.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Becke, A.D. Density‐functional thermochemistry. IV. A new dynamical correlation functional and implications for exact‐exchange mixing. J. Chem. Phys., 1996, 104(3), 1040-1046. doi: 10.1063/1.470829</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Perdew, J.P.; Kurth, S.; Zupan, A.; Blaha, P. Accurate density functional with correct formal properties: A step beyond the generalized gradient approximation. Phys. Rev. Lett., 1999, 82(12), 2544-2547. doi: 10.1103/PhysRevLett.82.2544</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Dennington, R.D.; Keith, T.A.; Millam, J.M. GaussView 5.0; Gaussian Inc.: Wallingford, 2008, p. 20.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep., 2017, 7(1), 42717. doi: 10.1038/srep42717 PMID: 28256516</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Han, Y.; Zhang, J.; Hu, C.Q.; Zhang, X.; Ma, B.; Zhang, P. In silico ADME and toxicity prediction of ceftazidime and its impurities. Front. Pharmacol., 2019, 10, 434-445. doi: 10.3389/fphar.2019.00434 PMID: 31068821</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Lafitte, D.; Lamour, V.; Tsvetkov, P.O.; Makarov, A.A.; Klich, M.; Deprez, P.; Moras, D.; Briand, C.; Gilli, R. DNA gyrase interaction with coumarin-based inhibitors: The role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose. Biochemistry, 2002, 41(23), 7217-7223. doi: 10.1021/bi0159837 PMID: 12044152</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Holdgate, G.A.; Tunnicliffe, A.; Ward, W.H.J.; Weston, S.A.; Rosenbrock, G.; Barth, P.T.; Taylor, I.W.F.; Pauptit, R.A.; Timms, D. The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: A thermodynamic and crystallographic study. Biochemistry, 1997, 36(32), 9663-9673. doi: 10.1021/bi970294+ PMID: 9245398</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Tian, W.; Chen, C.; Lei, X.; Zhao, J.; Liang, J. CASTp 3.0: Computed atlas of surface topography of proteins. Nucleic Acids Res., 2018, 46(W1), W363-W367. doi: 10.1093/nar/gky473 PMID: 29860391</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Taylor, S.N.; Marrazzo, J.; Batteiger, B.E.; Hook, E.W., III; Seña, A.C.; Long, J.; Wierzbicki, M.R.; Kwak, H.; Johnson, S.M.; Lawrence, K.; Mueller, J. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N. Engl. J. Med., 2018, 379(19), 1835-1845. doi: 10.1056/NEJMoa1706988 PMID: 30403954</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Basarab, G.S.; Kern, G.H.; McNulty, J.; Mueller, J.P.; Lawrence, K.; Vishwanathan, K.; Alm, R.A.; Barvian, K.; Doig, P.; Galullo, V.; Gardner, H.; Gowravaram, M.; Huband, M.; Kimzey, A.; Morningstar, M.; Kutschke, A.; Lahiri, S.D.; Perros, M.; Singh, R.; Schuck, V.J.A.; Tommasi, R.; Walkup, G.; Newman, J.V. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci. Rep., 2015, 5(1), 11827. doi: 10.1038/srep11827</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Dong, Y.; Liao, M.; Meng, X.; Somero, G.N. Structural flexibility and protein adaptation to temperature: Molecular dynamics analysis of malate dehydrogenases of marine molluscs. Proc. Natl. Acad. Sci., 2018, 115(6), 1274-1279. doi: 10.1073/pnas.1718910115 PMID: 29358381</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Parr, R.G.; Donnelly, R.A.; Levy, M.; Palke, W.E. Electronegativity: The density functional viewpoint. J. Chem. Phys., 1978, 68(8), 3801-3807. doi: 10.1063/1.436185</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Chattaraj, P.K.; Sarkar, U.; Roy, D.R. Electrophilicity Index. Chem. Rev., 2006, 106(6), 2065-2091. doi: 10.1021/cr040109f PMID: 16771443</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Koopmans, T. About the assignment of wave functions and eigenvalues to the individual electrons of an atom. Physica, 1934, 1, 104-113. doi: 10.1016/S0031-8914(34)90011-2</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Miar, M.; Shiroudi, A.; Pourshamsian, K. Theoretical investigations on the HOMOLUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzodthiazole-2(3H)-imine and its para-substituted derivatives: Solvent and subs. J. Chem. Res., 2021, 45, 147-158. doi: 10.1177/1747519820932091</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Ruiz-Morales, Y. HOMO-LUMO gap as an index of molecular size and structure for Polycyclic Aromatic Hydrocarbons (PAHs) and asphaltenes: A theoretical study. I. J. Phys. Chem. A, 2002, 106(46), 11283-11308. doi: 10.1021/jp021152e</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Han, M.İ.; Dengiz, C.; Doğan, Ş.D.; Gündüz, M.G.; Köprü, S.; Özkul, C. Isoquinolinedione-urea hybrids: Synthesis, antibacterial evaluation, drug-likeness, molecular docking and DFT studies. J. Mol. Struct., 2022, 1252, 132007. doi: 10.1016/j.molstruc.2021.132007</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Fonteh, P.; Elkhadir, A.; Omondi, B.; Guzei, I.; Darkwa, J.; Meyer, D. Impedance technology reveals correlations between cytotoxicity and lipophilicity of mono and bimetallic phosphine complexes. Biometals, 2015, 28(4), 653-667. doi: 10.1007/s10534-015-9851-y PMID: 25829148</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Barret, R. Importance and evaluation of the polar surface area (PSA and TPSA). In: Therapeutical Chemistry; , 2018; p. 89-95.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Qidwai, T. QSAR modeling, docking and ADMET studies for exploration of potential anti-malarial compounds against Plasmodium falciparum. In Silico Pharmacol., 2017, 5(1), 6. doi: 10.1007/s40203-017-0026-0 PMID: 28726171</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Dahlgren, D.; Lennernäs, H. Intestinal permeability and drug absorption: Predictive experimental, computational and in vivo approaches. Pharmaceutics, 2019, 11(8), 411. Epub ahead of print doi: 10.3390/pharmaceutics11080411 PMID: 31412551</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Martin, Y.C. A bioavailability score. J. Med. Chem., 2005, 48(9), 3164-3170. doi: 10.1021/jm0492002 PMID: 15857122</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Muhammed, M.T.; Kuyucuklu, G.; Kaynak-Onurdag, F.; Aki-Yalcin, E. Synthesis, antimicrobial activity, and molecular modeling studies of some benzoxazole derivatives. Lett. Drug Des. Discov., 2022, 19(8), 757-768. doi: 10.2174/1570180819666220408133643</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Doherty, A.T.; Hayes, J.E.; Molloy, J.; Wood, C.; ODonovan, M.R. Bone marrow micronucleus frequencies in the rat after oral administration of cyclophosphamide, hexamethylphosphoramide or gemifloxacin for 2 and 28 days. Toxicol. Res., 2013, 2(5), 321-327. doi: 10.1039/c3tx50028d</mixed-citation></ref></ref-list></back></article>
